Stockholm 17:30
-0,73% Idag
+6,21% Sedan årsskifte
-0,01% OMXSPI

2018-05-04 09:00:00

2cureX releases new information brochure

Today 2cureX has released a new information brochure. The brochure is available for download here.

2cureX - teaser-May 2018 ( (.PDF)

Certified Adviser

Sedermera Fondkommission is the Certified Adviser of 2cureX.

For more information about 2cureX:

Ole Thastrup, CEO


Phone: +45 22 11 53 99


About 2cureX

2cureX has developed IndiTreat® (Individual Treatment Design) - a patented method for selecting the right drug for the right patient, thereby improving cancer treatment. Initially, IndiTreat® is targeted towards colorectal cancer; but the method is applicable to additional cancer indications (e.g. ovarian, breast and kidney cancer). The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol "2CUREX"). 

Attached html: HTML
Attached pdf: PDF
Attached pdf: PDF